PHILADELPHIA, Oct. 11, 2007 (PRIME NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) announced today that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for its experimental therapeutic, Ampligen(r), also known as Poly I : Poly C12U, to treat Chronic Fatigue Syndrome ("CFS"). The Company is also moving forward as planned with filings in countries outside the United States.
